In the first randomized controlled trial to investigate the use of a 2-in-1 inhaler as the sole reliever therapy for children aged 5 to 15, an international team found the combined treatment to be ...

Add Yahoo as a preferred source to see more of our stories on Google. A new study shows that a dual-action inhaler cuts asthma attacks in children almost in half. (CREDIT: Imperial College London) For ...

As reliever monotherapy for mild asthma, the inhaled corticosteroid (ICS)-formoterol combination reduced asthma attacks in children compared with a short-acting β₂-agonist (SABA), the CARE trial ...

Findings from a first-of-its-kind virtual trial in pulmonary medicine, conducted at Rutgers and many other institutions, suggest adding an inhaled corticosteroid to rescue therapy could sharply reduce ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomised controlled trial to investigate the use of a ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...

(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) announced a major update to the U.S. prescribing information for AIRSUPRA, following new clinical evidence from the BATURA study. This Phase IIIb ...

Please provide your email address to receive an email when new articles are posted on . Patients with mild asthma are still at risk for severe exacerbations, which can impact their quality of life.

Mild asthma could be better treated with the recent approval of the combination of albuterol/budesonide. This is a real game changer. Why? The drug Airsupra, that is the combination of ...

Realising you've left home without your inhaler can be genuinely frightening if you have asthma. This quick onset of panic ...

A new study found that a 2-in-1 anti-inflammatory inhaler reduced asthma attacks in children by 45% compared to the widely-used salbutamol inhaler. The corresponding study was published in The Lancet.